WT1 and leukemia: Despite its ubiquitous expression during embryogenesis, WT1 expression in normal individuals is limited to renal podocytes, gonadal cells, and CD34+ bone marrow cells [102,103], where expression is significantly lower than in leukaemia cells (10–100 fold) [103], making it an excellent target for immunotherapy.